Global Gastric Cancer Therapy Market growth expected to be driven by rising onshore and offshore dri

Despite significant progress in the treatment of gastric cancer, it is still among the leading cause of deaths due to cancer, across the world. The high mortality rates are primarily caused by the late diagnosis of the disease, with patients often missing the opportunity for a surgical cure and cancer already having been developed into an advanced stage when identified. Gastric cancer is common cancer, found, especially in the developing economies of East Asia, Middle, and East Europe, and South America. Cases of gastric cancer in China account for 44.2% of the global new gastric cancer cases. According to the estimates of GLOBOCAN 2018, the number of incident cases of stomach cancer in Asia in 2018 was about 769,728, and it is expected to increase to 947,186, by 2025. According to the estimates of GLOBOCAN, in 2018, South Korea had the highest rate of stomach cancer, followed by Mongolia. While in men the stomach cancer rate in South Korea was 57.8, in women it was about 23.5, in 2018. Although chemotherapy can improve the chances of survival for patients with advanced gastric cancer, the overall survival rate is still very low. A significant number of studies have shown that molecular targeted therapy can further improve the survival rates of patients with gastric cancer. Recently, chemotherapeutic agents – pembrolizumab and ramucirumab, for the treatment of gastric cancer. Due to the increasing number of molecular studies of gastric cancers, new molecular targeted drugs ha....

read more from montana-ledger.com